Skip to main content
SpringerLink
Log in

Molecular and Cell Biology of Human Gene Therapeutics

  • Book
  • © 1995

Overview

Editors:
  1. George Dickson

    1. Department of Biochemistry, Royal Holloway, University of London, Egham, Surrey, UK

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Molecular and Cell Biology of Human Diseases Series (Mol. Cell Biol. Hu. Dis., volume 20)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (18 chapters)

  1. Front Matter

    Pages i-xv
    Download chapter PDF

  2. Retroviral vectors

    • Ariberto Fassati, Matthew G. Dunckley, George Dickson
    Pages 1-19

  3. Adenoviral vectors

    • Martin G. Lee, Eric J. Kremer, Michel Perricaudet
    Pages 20-32

  4. Herpes simplex virus vectors

    • Joseph Glorioso, Mary Ann Bender, David Fink, Neal Deluca
    Pages 33-63

  5. Liposome-mediated gene transfer

    • Itaru Yanagihara, Yasufumi Kaneda, Koji Inui, Shintaro Okada
    Pages 64-82

  6. Intramuscular injection of plasmid DNA

    • Dominic J. Wells
    Pages 83-103

  7. Yeast artificial chromosome vectors

    • Stewart A. Fabb, Jiannis Ragoussis
    Pages 104-124

  8. Gene transfer and cancer chemotherapy

    • Donald W. Moorman, Kenneth W. Culver
    Pages 125-139

  9. Vaccine immunotherapy for cancer

    • John Bridgewater, Mary Collins
    Pages 140-156

  10. Inherited immunodeficiencies

    • Christine Kinnon
    Pages 157-174

  11. Anti-viral strategies

    • Marinee K. L. Chuah, Thierry Vandendriessche, Richard A. Morgan
    Pages 175-194

  12. AIDS and HIV infection

    • Clay Smith, Bruce A. Sullenger
    Pages 195-236

  13. Cystic fibrosis and lung diseases

    • Samuel C. Wadsworth, Alan E. Smith
    Pages 237-251

  14. Arthritis

    • Christopher H. Evans, Paul D. Robbins
    Pages 252-260

  15. Duchenne muscular dystrophy

    • George Dickson, Susan C. Brown
    Pages 261-280

  16. Cardiovascular disease

    • Howard Prentice, Keith A. Webster
    Pages 281-300

  17. Degenerative and inherited neurological disorders

    • Pedro R. Lowenstein
    Pages 301-349

  18. Mucopolysaccharidosis

    • Olivier Danos, Jean-Michel Heard
    Pages 350-367

  19. DNA-based immunization

    • Heather L. Davis, Robert G. Whalen
    Pages 368-387

  20. Back Matter

    Pages 388-403
    Download chapter PDF
Back to top

Keywords

About this book

advanced metastatic disease of solid tumors, dictates that each tumor mass, indeed each individual metastasis, will have a unique antigen and cytokine environment and hence unique response to immune modu­ lation. A differential response to immunotherapy is thus inevitable. 4. Many of the human trials described are not randomized and report survival or response against historical controls. Most tumors described are immunogenic human tumors: renal cell cancer and melanoma are most common. In order to avoid the well-described inter-patient vari­ ation and rare incidence of spontaneous response among patient samples as well as selection bias and changes in practice over time, randomized trials are required. 5. Immunological treatment is unlike conventional chemotherapy in its endpoint. Most chemotherapeutic regimes require a complete response or a good partial response for cure or good palliation. There are now many cases where immunotherapy has provided long-term palliation without massive tumor reduction. Immunity may be stimulated to a degree which holds tumorigenicity in check and most importantly, pro­ vides good palliation for the patient in a manner that differs essentially from chemotherapy.

Editors and Affiliations

  • Department of Biochemistry, Royal Holloway, University of London, Egham, Surrey, UK

    George Dickson

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation